alliance

OpGen's research-use-only Acuitas AMR Gene Panel u5.47 is designed to detect multidrug-resistant bacterial pathogens in urine or bacterial isolates.

Oxford BioDynamics has developed a platform for discovering, evaluating, validating, and monitoring a unique class of epigenetic biomarkers.

The company cites flexibility and ease of use as its main selling points, and is partnering with IVD firms like Randox and R-Biopharm on assay development.

Genetic Technologies and Blockchain Global may partner to develop medical and biotechnology applications that combine their respective technologies.

The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.

Thermo Fisher will sell Synthego's synthetic guide RNA products under the Invitrogen TrueGuide brand. 

The alliance will combine the two firms' technologies and know-how to provide doctors with insights into patients' health status.

PSS, which develops tools for the IVD space, will supply to Hitachi its nucleic acid isolation system, fully automated diagnostic instruments, and reagents.

Under the terms of the deal, Siemens will expand its kPCR Molecular System menu to include Fast-track's range of tests covering several medical conditions. 

The program aims to assist hundreds of people diagnosed with PKU to obtain simple and affordable access to mutation analysis of the PAH gene. 

Pages

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.